Startpage

Isofol Medical’s Board of Directors intends to call an extraordinary general meeting with proposals for dividends and liquidation of the company

GOTHENBURG, Sweden, January 19, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), decided today to call an extraordinary general meeting to take a decision on a cash dividend of the maximum amount of capital available and to decide that the company is to be liquidated. The assessment is based on a thorough analysis of Isofol’s future opportunities after the negative outcome of the company’s phase III study (AGENT) and aims to ensure that as large a part of the company’s remaining assets as possible benefit the shareholders.

CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023

GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that Chief Executive Officer Dr. Ulf Jungnelius M.D. and Isofol’s Board of Directors have agreed that Ulf will step down as CEO of Isofol on June 1, 2023. Isofol’s Board of Directors will take a decision regarding a new CEO once the company’s future has been determined.

Final data from the AGENT study confirms topline results

GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT study’s final data confirmed topline results presented on August 3, 2022. Moreover, no predictive gene expressions for clinical response could be identified. Isofol is continuing its efforts to terminate the AGENT study in line with applicable ethical and regulatory requirements, complete the final study report for submission to regulatory agencies and prepare a manuscript for a scientific publication. Isofol is in parallel continuing to investigate possible future paths forward for the company.

Isofol Medical AB (publ) appoints Jenny Sundqvist as Chief Commercial Officer

GOTHENBURG, Sweden, December 10, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced the appointment of Jenny Sundqvist as Chief Commercial Officer (CCO) as of January 1, 2022. Jenny is currently the Head of Commercial and Strategy Development at Isofol. Former CCO, Tony Gustavsson, leaves Isofol for a new international assignment in a global pharmaceutical group.

Scroll to Top